2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of …
CT January, LS Wann, H Calkins, LY Chen… - Circulation, 2019 - Am Heart Assoc
The purpose of this document is to update the “2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task …
CT January, LS Wann, JS Alpert, H Calkins… - Journal of the American …, 2014 - jacc.org
The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …
extensive evidence review was conducted, focusing on 2006 through October 2012 and …
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and …
European Journal of Preventive Cardiology, 2012 - journals.sagepub.com
Atherosclerotic cardiovascular disease (CVD) is a chronic disorder develo** insidiously
throughout life and usually progressing to an advanced stage by the time symptoms occur. It …
throughout life and usually progressing to an advanced stage by the time symptoms occur. It …
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American …
The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …
extensive evidence review was conducted, focusing on 2006 through October 2012 and …
Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based …
Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …
therapeutic index medications as effective and safe as possible. This article focuses on the …
Pulmonary embolism and deep vein thrombosis
Pulmonary embolism is the third most common cause of death from cardiovascular disease
after heart attack and stroke. Sequelae occurring after venous thromboembolism include …
after heart attack and stroke. Sequelae occurring after venous thromboembolism include …
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
In July 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …
Review included limited searches for new evidence and discussion of the search results …
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis
Background Near-patient testing has made self-monitoring of anticoagulation with warfarin
feasible, and several trials have suggested that such monitoring might be equal to or better …
feasible, and several trials have suggested that such monitoring might be equal to or better …
Vitamin K antagonists in heart disease: Current status and perspectives (Section III)
R De Caterina, S Husted, L Wallentin… - Thrombosis and …, 2013 - thieme-connect.com
Oral anticoagulants are a mainstay of cardiovascular therapy, and for over 60 years vitamin
K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere with …
K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere with …